FIELD: medicine; neurology.
SUBSTANCE: invention can be used to predict the stage of multiple sclerosis. The percentage of CD3 T-lymphocytes expressing NK-associated antigens CD16+CD56+ on their surface and the percentage of CD19 B-lymphocytes expressing CD5, CD25, CD38, CD40, CD95 antigens on their surface are determined. The coefficient of the stage of multiple sclerosis is calculated using the numerical values of the obtained percentages of these indicators in the regression equation according to the formula: Cms=NKT*1.59-CD5*0.04-CD25*0.26-CD38*0.2-CD40*0.12+CD95*0.1+9.43, where NKT is the numerical value of the percentage of T-lymphocytes expressing NK-associated antigens CD16+CD56+ on their surface, CD5 is numerical value of the percentage of B-lymphocytes expressing CD5 antigen on their surface, CD25 is numerical value of the percentage of B-lymphocytes expressing CD25 antigen on their surface, CD38 is numerical value of the percentage of B-lymphocytes expressing the CD38 antigen on their surface, CD40 is numerical value of the percentage of B-lymphocytes expressing the CD40 antigen on their surface, CD95 is numerical value of the percentage of B-lymphocytes expressing the CD95 antigen on their surface, 9.43 is a constant coefficient. If Cms value is equal to or less than 0, then the stage of remission of multiple sclerosis is predicted; if Cms value is more than 0, the stage of exacerbation of multiple sclerosis is predicted.
EFFECT: invention provides accurate prediction of the further course of multiple sclerosis.
1 cl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF PREDICTING BEGINNING OF CHRONIC OBSTRUCTIVE LUNG DISEASE | 2009 |
|
RU2407012C1 |
METHOD OF PRODUCING CYTOTOXIC LYMPHOCYTES USING IFN-γ AND TNF-α FOR ADOPTIVE IMMUNOTHERAPY | 2023 |
|
RU2822876C2 |
BIOMEDICAL CELL PRODUCT WITH ANTI-HER2 SPECIFIC ANTI-TUMOUR ACTIVITY | 2019 |
|
RU2728361C1 |
METHOD FOR PREDICTION OF DEVELOPING MULTIPLE SCLEROSIS TAKING INTO ACCOUNT IMMUNE-METABOLIC VALUES | 2013 |
|
RU2528879C1 |
METHOD FOR PREDICTION OF STAGE OF MULTIPLE SCLEROSIS TAKING INTO ACCOUNT VALUES OF IMMUNOLOGICAL STATUS | 2013 |
|
RU2528882C1 |
METHOD OF PREDICTING RESISTANCE TO INFECTIOUS DISEASES IN CHILD OF FIRST YEAR OF LIFE | 2014 |
|
RU2553356C1 |
BIOMEDICAL CELL PRODUCT WITH SPECIFIC ANTITUMOR ACTIVITY, REPRESENTED BY POPULATIONS OF LYMPHOKINE-ACTIVATED KILLERS AND ANTI-HER2 CAR-γδΤ-OIL AND ANTI-HER2 CAR-T-NK | 2022 |
|
RU2786210C1 |
METHOD OF THERAPY OF REMITTENT MULTIPLE SCLEROSIS | 2012 |
|
RU2523058C2 |
DIAGNOSTIC TECHNIQUE FOR HEPATIC CIRRHOSIS (STAGE F4) IN THE OUTCOME OF CHRONIC VIRAL HEPATITIS C | 2019 |
|
RU2724595C1 |
LACTOBACILLUS APPLICATION FOR TREATING AUTOIMMUNE DISEASES | 2006 |
|
RU2417092C2 |
Authors
Dates
2024-01-12—Published
2023-07-13—Filed